Markers for efficacy of mammalian target of rapamycin inhibitor.

Abstract

Mammalian target of rapamycin (mTOR), an important sensor for growth factors, nutritional deprivation and other stresses in controlling translation, plays a critical role in tumorigenesis. Several rapalogs exhibited antitumor activity clinically, with a modest average response rate, while a small subset of patients exhibited significantly greater clinical benefits. A better understanding of cellular mechanisms and the results of clinical studies can help identify an optimal biomarker to predict the efficacy of mTOR inhibitors. We discuss these potential markers in terms of selection of candidates, baseline expression, pathway inhibition and source of targeted protein.

• Authors: Yu-Min Liao, Alex Sy, Yun Yen
• Journal: Anticancer research (Anticancer Res) Vol. 32 Issue 10 Pg. 4235-44 (Oct 2012) ISSN: 1791-7530 [Electronic] Greece
• PMID: 23060543 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Biomarkers, Pharmacological
• MTOR protein, human
• mTOR protein, mouse
• TOR Serine-Threonine Kinases

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Biomarkers, Pharmacological (analysis, metabolism)
• Humans
• Mice
• Neoplasms (drug therapy)
• Signal Transduction (drug effects)
• TOR Serine-Threonine Kinases (antagonists & inhibitors)